Current Clinical Trials

Multiple Myeloma

CAR-T:

  • A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed within one year of Initial Treatment (NCT03601078)

Acute Myeloid Leukemia (AML)

CAR-T

  • A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (NCT04789408)

NK Cells:

  • A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation (NCT02782546) 
  • Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML after Allogeneic Hematopoietic Cell Transplant in Children and Adults (NCT03068819)

Myelodysplastic Syndromes (MDS)

None currently listed

Chronic Lymphocytic Leukemia (CLL)

CAR-T:

  • A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies (NCT05643742)

Acute Lymphoblastic Leukemia (ALL)

CAR-T:

  • An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (NCT04404660)
  • A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART -007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL) (NCT04984356)
  • A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies (NCT04035434)

T-cell Lymphoblastic Lymphoma (T-LBL)

CAR-T

  • A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART -007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL) (NCT04984356)

Post-Transplant Lymphoproliferative Disorder (PTLD) & Epstein-Barr Virus (EBV) Malignancies

Viral Cytotoxic Lymphocytes:

  • An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases (NCT04554914)  
  • Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (NCT03394365)

Hairy Cell Leukemia

  • A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) (NCT05537766)

Lymphoma

CAR-T:

  • Serum neurofilament light (NfL) as a marker for brain injury in individuals undergoing chimeric antigen receptor-modified T therapy (NCT04614987)  
  • A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies (NCT04035434)
  • A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (efineptakin alfa) a Long-acting Human IL-7, post-Tisagenlecleuel (Kymriah®) in Subjects with Relapsed/Refractory Large B-cell Lymphoma (NCT04831320)
  • Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy (NCT05044039)
  • A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) (NCT05537766)
  • A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies (NCT05643742)

Solid Tumors

TCR Modified T Cells

  • A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies (NCT02636855)   
  • A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 STUDY) (NCT04044768)   
  • A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (NCT04044859)

Tumor-Infiltrating Lymphocytes (TILs):

  • An Expanded Access Program of Lifileucel, Autologous Tumor Infiltrating Lymphocytes (TIL; LN-144), for Patients with Unresectable or Metastatic Melanoma (NCT05398640)

Observational:

  • BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing (NCT04981119)